Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H3 | Q13133 | 3/20 | 0.55 |
| ▸ | RORC | P51449 | 13/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | NR1I2 | O75469 | 5/20 | 0.48 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3617770 | 0.90 | NR1H3 (0.53) | NR1H3RORCTP53NR1I2 | |
| SCHEMBL14537975 | 0.89 | TP53 (0.50) | NR1H3RORCTP53LMNATHRB | |
| SCHEMBL3621272 | 0.84 | NR1H3 (0.58) | NR1H3RORCNR1I2LMNAMAPT | |
| SCHEMBL3627747 | 0.84 | NR1H3 (0.58) | NR1H3RORCTP53LMNAMAPT | |
| SCHEMBL3623893 | 0.83 | NR1H3 (0.49) | NR1H3RORCNR1I2 | |
| SCHEMBL4860748 | 0.83 | TP53 (0.55) | TP53LMNATHRBMAPT | |
| SCHEMBL3623583 | 0.82 | NR1H3 (0.56) | NR1H3RORCTP53NR1I2MAPT | |
| SCHEMBL3619484 | 0.82 | NR1H3 (0.55) | NR1H3RORCNR1I2 | |
| SCHEMBL4871152 | 0.82 | TP53 (0.56) | TP53LMNATHRBMAPT | |
| SCHEMBL3626841 | 0.81 | NR1H3 (0.61) | NR1H3RORCLMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7741317-B2 | LXR modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-06-22 | — | — | US | disclosed |
| US-7741317-B2 | LXR modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-06-22 | — | — | US | disclosed |
| US-7741317-B2 | LXR modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-06-22 | — | — | US | disclosed |
| US-20070093470-A1 | LXR modulators | BRISTOL-MYERS SQUIBB COMPANY | 2007-04-26 | — | — | US | disclosed |
| US-20070093470-A1 | LXR modulators | BRISTOL-MYERS SQUIBB COMPANY | 2007-04-26 | — | — | US | disclosed |
| US-20070093470-A1 | LXR modulators | BRISTOL-MYERS SQUIBB COMPANY | 2007-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070093470-A1 | LXR modulators | NR1H2, NR1H3, RXRB | NR1H3 2/4885RORC 66/4885TP53 4158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.